durvalumab
astrazeneca
['renal,(-adrenal)', 'durva', 'durvalumab']
asco 2022: met and ctla-4 inhibition fail to add benefit to durvalumab therapy in advanced clear cell renal cancer #oncology
Official Twitter account of @PracticeUpdate Oncology. Includes commentaries, journal scans, conference coverage, news items & more. Part of Elsevier.